Stockscreener 앱 받기
0.7679
2.94%
0.0219
전일 마감가:
$0.746
열려 있는:
$0.7699
하루 거래량:
11,705
Relative Volume:
0.18
시가총액:
$81.21M
수익:
$5.61M
순이익/손실:
$-42.51M
주가수익비율:
-1.6479
EPS:
-0.466
순현금흐름:
$-16.86M
1주 성능:
-8.56%
1개월 성능:
-19.49%
6개월 성능:
-4.63%
1년 성능:
-57.10%
1일 변동 폭
$0.75
$0.7699
1주일 범위
$0.7425
$0.8598
52주 변동 폭
$0.4912
$2.25
Citius Oncology Inc Stock (CTOR) Company Profile
명칭
Citius Oncology Inc
전화
(908) 967-6677
주소
11 COMMERCE DRIVE, CRANFORD
Compare CTOR vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.7679 | 81.21M | 5.61M | -42.51M | -16.86M | -0.466 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-23 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-11-27 | 개시 | Maxim Group | Buy |
Citius Oncology Inc 주식(CTOR)의 최신 뉴스
Citius Oncology Announces Results of 2026 Annual Stockholder Meeting Votes - Kalkine Media
Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com Canada
Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com UK
CTXR Stock Price, Quote & Chart - ChartMill
Citius Pharma CEO to speak at two New York conferences - Stock Titan
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire
CITIUS ONCOLOGY, INC. SEC Filing (Aug 26, 2026) - Stock Titan
Citius (CTOR) Quarterly Results: The EPS Result Is Below Expectation in the Latest Session; Session Move: Shares Finish 2.02% Lower on the DayEPS Surprise History - vinanet.vn
Enterprise value to EBIT forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Armistice Capital Expands Citius Oncology (CTOR) Stake Despite Distress Signals - GuruFocus
Citius (CTOR) Quarterly Results: Reported EPS Misses Expectations in the Reported Period; After Results: The Market Price Advances 6.97% on the DayForward Guidance Trends - vinanet.vn
Citius Oncology Shares Slide 10% After Fiscal Q3 Revenue Misses Estimates Despite LYMPHIR Launch Gains - dars.gov.et
Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance
Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com Australia
Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com
Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com
Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard
CTOR Q2 2026 Earnings: Pre-Revenue Loss Misses Badly, Yet Shares Jump 10%EBITDA Analysis - vinanet.vn
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st
Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - minichart.com.sg
Citius Oncology Posts First Revenue from LYMPHIR Launch as Institutional Demand Surges 31% - Minichart
Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan
Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade
Citius Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI
CTOR: LYMPHIR launch drove $7.1M revenue and 31% sequential vial order growth, with broad payer access - TradingView
Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneInverse ETF Flow - vinanet.vn
Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake - Stock Titan
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneRSI Oversold Picks - siam.in
Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneIsland Reversal - dars.gov.et
Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan
Citius Oncology appoints independent director Peri to board of directors - ROI-NJ
Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia
People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar
Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union
Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com South Africa
Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Australia
Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Canada
Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Nigeria
Citius Oncology adds independent director to expanded board - TipRanks
Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Nigeria
Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com India
Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia
Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz
Citius Oncology Inc (CTOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.72%
0.93%
자본화:
|
볼륨(24시간):